According to Zacks, “Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company’s business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany. “
FSNUY has been the subject of several other research reports. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of FRESENIUS SE &/S in a research note on Friday, August 14th. Jefferies Financial Group lowered shares of FRESENIUS SE &/S from a “hold” rating to an “underperform” rating in a research note on Wednesday, August 5th. ValuEngine lowered shares of FRESENIUS SE &/S from a “hold” rating to a “sell” rating in a research note on Thursday, July 9th. Morgan Stanley upgraded shares of FRESENIUS SE &/S from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, May 20th. Finally, Barclays restated an “equal weight” rating on shares of FRESENIUS SE &/S in a research note on Monday, June 1st. Two analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $13.00.
FRESENIUS SE &/S (OTCMKTS:FSNUY) last released its quarterly earnings data on Thursday, July 30th. The company reported $0.20 earnings per share for the quarter. The company had revenue of $9.82 billion during the quarter. FRESENIUS SE &/S had a net margin of 5.05% and a return on equity of 6.78%. On average, analysts anticipate that FRESENIUS SE &/S will post 0.93 EPS for the current fiscal year.
FRESENIUS SE &/S Company Profile
Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for FRESENIUS SE &/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FRESENIUS SE &/S and related companies with MarketBeat.com's FREE daily email newsletter.